ClinicalTrials.gg
TerminatedNCT02201524Updated Oct 5, 2016Results posted

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

A Phase 2 interventional study of PF-04965842 and PF-04965842 in Plaque Psoriasis, sponsored by Pfizer. Terminated at 45 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Psoriasis by Pfizer — none open to participants now, none under way, none of them phase 3. Psoriasis · Pfizer.

Enrollment
32nd of 42
59 · median 120
Started
2014
with 3 others
Phase 2
13 of 57
none open now
Registered
47th of 57
by date

Among the 57 studies in Psoriasis by Pfizer, this one is the 32nd largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2014, is one of 13 in phase 2, and was the 47th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 57 studies in Psoriasis by Pfizer is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies in Psoriasis by Pfizer as a file.
02

Study summary

Study B7451005 is a Phase 2 study which will assess the efficacy and safety of PF-04965842 in patients with moderate to severe psoriasis. The study will include three PF-04965842 groups (200 mg daily, 400 mg daily and 200 mg twice daily) and a placebo group. The treatment period will be 4 weeks in duration and will be followed up by a 4 week follow up period.

03

Conditions studied

  • Plaque Psoriasis

Keywords

  • Phase 2
  • randomized
  • double-blind
  • placebo
  • plaque
  • psoriasis
  • safety
  • efficacy
  • JAK
  • janus kinase
  • moderate
  • severe
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose.
  2. Have plaque type psoriasis covering at least 15% of total BSA at Day 1 (at the time of the first study dose).
  3. Have a PASI score of 12 or greater at Day 1 (at the time of the first study dose).
  4. Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment).

Exclusion criteria

Exclusion Criteria:

  1. Currently have non plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular psoriasis.
    1. Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.
  2. Have received any of the following treatment regimens specified in the timeframes outlined below:

Within 9 months of first dose of study drug:

  • Ustekinumab (Stelara).

Within 12 weeks of first dose of study drug:

  • Any experimental therapy for psoriasis or rheumatoid arthritis.

Within 4 8 weeks of first dose of study drug:

  • Biologic therapies for psoriasis have discontinuation periods determined from approximately 5x half life of the respective biologic:
  • 4 weeks: etanercept (Enbrel).
  • 8 weeks: infliximab (Remicade), adalimumab (Humira).

Within 4 weeks of first dose of study drug:

  • Systemic treatments other than biologics that could affect psoriasis (eg, oral or injectable , retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine).
  • Phototherapy and psoralen plus ultraviolet A therapy (PUVA).
  • Other - intramuscular gold, immunization with any (eg, FluMist), herbal medications.

Within 2 weeks of first dose of study drug:

  • Topical treatments that could affect psoriasis (eg, corticosteroids, tars, keratolytics, anthralin, vitamin D analogs, and retinoids).
  • Phototherapy with ultraviolet B (UVB) (narrowband or broadband).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Cohort 1

    200mg of PF-04965842 twice daily

    Drug: PF-04965842

  • Experimental
    Cohort 2

    400mg of PF-04965842 once daily

    Drug: PF-04965842

  • Experimental
    Cohort 3

    200mg of PF-04965842 once daily

    Drug: PF-04965842

  • Placebo comparator
    Cohort 4

    Placebo comparator daily

    Other: Placebo

Interventions

  • Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks

    Also known as: JAK1 inhibitor

  • Subjects will receive 400 mg PF 04965842 daily for 4 weeks

    Also known as: JAK1 inhibitor

  • Subjects will receive 200 mg PF 04965842 daily for 4 weeks

    Also known as: JAK1 inhibitor

  • OtherPlacebo

    Subjects will receive placebo for 4 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 4

    PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Percent Change From Baseline in PASI Score at Week 1, 2, 3, 4, 5, 6, and 8

    PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8

  2. Change From Baseline in PASI Score at Week 1, 2, 3, 5, 6 and 8

    PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

    Time frame: Baseline, Week 1, 2, 3, 5, 6, 8

  3. Percentage of Participants Achieving 50 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8

    PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 50 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8

  4. Percentage of Participants Achieving 75 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6 and 8

    PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 75 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8

  5. Percentage of Participants Achieving 90 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8

    PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 90 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)

  6. Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear' at Week 1, 2, 3, 4, 5, 6, and 8

    The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions. The severity rating scores (erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S= total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicating more severity. Participants with response of clear and almost clear were reported. 90 percent confidence intervals were calculated using clopper-pearson (exact) method.

    Time frame: Week 1, 2, 3, 4, 5, 6, 8

  7. Change From Baseline in Fasting Lipids at Week 2, 4 and 8

    Participants were required to fast 9 hours prior to sampling for lipid profile which included following parameters: low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), cholesterol, triglycerides.

    Time frame: Baseline, Week 2, 4, 8 (early termination)

  8. Change From Baseline in Lipid Ratios at Week 2, 4 and 8

    The ratio of LDL-C/HDL-C was reported.

    Time frame: Baseline, Week 2, 4, 8 (early termination)

  9. Change From Baseline in High Sensitivity C- Reactive Protein (hsCRP) at Week 1, 2, 3, 4, and 8

    The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Reference range for measurements is 0-0.5 mg/dL and lower limit of detection is less than (\<) 0.015 mg/dL. Any value \<0.015 mg/dL is imputed as 0.0075 mg/dL.

    Time frame: Baseline, Week 1, 2, 3, 4, 8 (early termination)

  10. Number of Participants Reporting Clinically Significant Change From Baseline in Epstein-Barr Virus (EBV) Values

    EBV samples were collected and changes from baseline were evaluated by the principal investigator (PI) for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in adverse event (AEs) or required follow-up.

    Time frame: Baseline up to Week 8 (early termination)

  11. Number of Participants Reporting Clinically Significant Change From Baseline in Cytomegalovirus (CMV) Values

    CMV samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.

    Time frame: Baseline up to Week 8 (early termination)

  12. Number of Participants Reporting Clinically Significant Change From Baseline in Herpes Simplex Virus Deoxyribonucleic Acid (HSV DNA) Values

    HSV DNA samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.

    Time frame: Baseline up to Week 8 (early termination)

  13. Change From Baseline in Blood Pressure (BP) at Week 1, 2, 3, 4, 5, 6, and 8

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)

  14. Change From Baseline in Pulse Rate at Week 1, 2, 3, 4, 5, 6, and 8

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)

  15. Change From Baseline in Respiratory Rate at Week 1, 2, 3, 4, 5, 6, and 8

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)

  16. Change From Baseline in Body Temperature at Week 1, 2, 3, 4, 5, 6, and 8

    Time frame: Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)

  17. Number of Participants Reporting Clinically Significant Change From Baseline in Heart Rate

    Time frame: Baseline up to Week 8 (early termination)

  18. Number of Participants Reporting Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters

    ECG change data was reported as qualitative results, as per change in planned analysis. It was categorized as: normal; abnormal, not clinically significant or abnormal, clinically significant.

    Time frame: Baseline up to Week 8 (early termination)

07

Results

Posted Oct 5, 2016
Limitations and caveats
The study was terminated early due to changes in the prioritization of the drug development portfolio and the early termination was not safety related.

Participant flow

Participant flow — Overall Study
MilestonePlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Started14151614
Completed12121210
Not completed2344
Withdrew: Adverse event0210
Withdrew: Insufficient clinical response1000
Withdrew: Lost to follow-up0020
Withdrew: No longer meets eligibility criteria0002
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject0011
Withdrew: Other1100

Outcome measures

PrimaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 4

PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

Time frame:
Baseline, Week 4
Reported as:
Mean · units on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 4
units on a scalePlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Baseline (n= 14, 15, 16, 14)20.05 ± 3.99320.34 ± 7.08919.21 ± 4.42618.01 ± 5.507
Change at Week 4 (n= 12, 12, 12, 10)-6.61 ± 7.252-11.73 ± 6.658-13.09 ± 7.979-13.71 ± 6.248
Statistical analysis
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Least square (ls) mean difference: -5.08 · 90% CI -9.15 to -1.01
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -5.61 · 90% CI -9.61 to -1.62
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -9.98 · 90% CI -14.19 to -5.77
SecondaryPercent Change From Baseline in PASI Score at Week 1, 2, 3, 4, 5, 6, and 8

PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8
Reported as:
Mean · percent change
Percent Change From Baseline in PASI Score at Week 1, 2, 3, 4, 5, 6, and 8
percent changePlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Change at Week 1 (n= 14, 15, 16, 14)-13.68 ± 18.527-23.27 ± 18.796-24.07 ± 22.272-30.99 ± 28.557
Change at Week 2 (n= 14, 14, 13, 12)-26.68 ± 25.776-27.96 ± 20.161-41.54 ± 28.779-49.09 ± 30.153
Change at Week 3 (n= 13, 12, 15, 11)-27.06 ± 31.220-33.96 ± 19.793-53.18 ± 33.326-73.37 ± 22.569
Change at Week 4 (n= 12, 12, 12, 10)-33.59 ± 31.574-57.61 ± 21.594-64.46 ± 32.175-80.96 ± 23.155
Change at Week 5 (n= 11, 12, 12, 9)-42.62 ± 21.228-58.63 ± 16.015-57.76 ± 37.397-80.80 ± 20.279
Change at Week 6 (n= 11, 11, 10, 10)-39.85 ± 28.661-61.02 ± 11.655-56.94 ± 39.558-69.15 ± 26.871
Change at Week 8 (n= 8, 11, 11, 8)-44.62 ± 26.616-44.28 ± 27.486-48.63 ± 35.373-61.67 ± 29.352
Statistical analysis
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -9.32 · 90% CI -23.19 to 4.56
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -11.19 · 90% CI -24.87 to 2.50
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -19.22 · 90% CI -33.45 to -4.99
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -4.30 · 90% CI -21.71 to 13.11
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -18.04 · 90% CI -35.25 to -0.82
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -27.07 · 90% CI -44.90 to -9.23
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -10.07 · 90% CI -28.53 to 8.39
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -29.23 · 90% CI -47.33 to -11.13
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -49.99 · 90% CI -68.92 to -31.05
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -24.25 · 90% CI -43.26 to -5.24
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -27.47 · 90% CI -46.18 to -8.75
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -52.63 · 90% CI -72.24 to -33.02
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · LANCOVA · Ls mean difference: -17.98 · 90% CI -35.80 to -0.15
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -14.78 · 90% CI -32.44 to 2.88
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -47.94 · 90% CI -66.61 to -29.27
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean: -21.75 · 90% CI -41.00 to -2.49
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -17.75 · 90% CI -36.92 to 1.42
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -35.88 · 90% CI -55.85 to -15.90
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -10.75 · 90% CI -32.57 to 11.07
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -13.03 · 90% CI -34.71 to 8.64
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -34.46 · 90% CI -57.44 to -11.48
SecondaryChange From Baseline in PASI Score at Week 1, 2, 3, 5, 6 and 8

PASI score is the combined assessment of lesion severity and area affected into single score range: 0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated: 0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4).

Time frame:
Baseline, Week 1, 2, 3, 5, 6, 8
Reported as:
Mean · units on a scale
Change From Baseline in PASI Score at Week 1, 2, 3, 5, 6 and 8
units on a scalePlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Change at Week 1 (n= 14, 15, 16, 14)-2.96 ± 4.306-5.13 ± 4.902-4.79 ± 4.900-5.46 ± 4.965
Change at Week 2 (n= 14, 14, 13, 12)-5.26 ± 5.205-5.80 ± 4.915-8.33 ± 7.103-8.51 ± 5.860
Change at Week 3 (n= 13, 12, 15, 11)-5.38 ± 7.033-7.44 ± 5.824-10.77 ± 8.048-12.61 ± 4.461
Change at Week 5 (n= 11, 12, 12, 9)-8.69 ± 5.314-11.68 ± 5.262-11.77 ± 8.421-14.17 ± 6.483
Change at Week 6 (n= 11, 11, 10, 10)-8.05 ± 6.989-12.00 ± 4.901-12.13 ± 9.576-11.80 ± 6.678
Change at Week 8 (n= 8, 11, 11, 8)-9.33 ± 6.745-8.38 ± 4.933-10.04 ± 8.287-10.75 ± 6.382
Statistical analysis
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -2.01 · 90% CI -4.73 to 0.72
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -2.31 · 90% CI -4.99 to 0.38
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -3.65 · 90% CI -6.45 to -0.86
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -1.08 · 90% CI -4.49 to 2.32
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -3.86 · 90% CI -7.23 to -0.49
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -5.16 · 90% CI -8.65 to -1.67
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -2.34 · 90% CI -6.07 to 1.39
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -6.12 · 90% CI -9.78 to -2.47
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -9.39 · 90% CI -13.22 to -5.56
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -3.25 · 90% CI -6.71 to 0.21
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -2.98 · 90% CI -6.40 to 0.45
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -8.59 · 90% CI -12.24 to -4.95
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -3.98 · 90% CI -7.89 to -0.08
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -3.80 · 90% CI -7.68 to 0.07
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -6.94 · 90% CI -11.00 to -2.89
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Ls mean difference: -1.27 · 90% CI -5.65 to 3.11
  • Placebo vs PF-04965842 400 mg Once Daily · Ls mean difference: -2.83 · 90% CI -7.18 to 1.51
  • Placebo vs PF-04965842 200 mg Twice Daily · Ls mean difference: -6.52 · 90% CI -11.15 to -1.89
SecondaryPercentage of Participants Achieving 50 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8

PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 50 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.

Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 50 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8
percentage of participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Week 1 (n= 14, 15, 16, 14)7.1 (0.4 to 29.7)6.7 (0.3 to 27.9)25.0 (9.0 to 48.4)21.4 (6.1 to 46.6)
Week 2 (n= 14, 14, 13, 12)21.4 (6.1 to 46.6)7.1 (0.4 to 29.7)23.1 (6.6 to 49.5)41.7 (18.1 to 68.5)
Week 3 (n= 13, 12, 15, 11)23.1 (6.6 to 49.5)25.0 (7.2 to 52.7)46.7 (24.4 to 70.0)90.9 (63.6 to 99.5)
Week 4 (n= 12, 12, 12, 10)25.0 (7.2 to 52.7)66.7 (39.1 to 87.7)66.7 (39.1 to 87.7)80.0 (49.3 to 96.3)
Week 5 (n= 11, 12, 12, 9)54.5 (27.1 to 80.0)66.7 (39.1 to 87.7)58.3 (31.5 to 81.9)100.0 (71.7 to 100)
Week 6 (n= 11, 11, 10, 10)45.5 (20.0 to 72.9)81.8 (53.0 to 96.7)60.0 (30.4 to 85.0)70.0 (39.3 to 91.3)
Week 8 (n= 8, 11, 11, 8)50.0 (19.3 to 80.7)45.5 (20.0 to 72.9)63.6 (35.0 to 86.5)62.5 (28.9 to 88.9)
Statistical analysis
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -0.5 · 90% CI -21.5 to 19.6
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 17.9 · 90% CI -5.9 to 40.3
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in Percentage Analysed using · Difference in percentage: 14.3 · 90% CI -9.3 to 38.0
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -14.3 · 90% CI -38.0 to 9.3
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 1.6 · 90% CI -25.4 to 29.1
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 20.2 · 90% CI -10.2 to 48.3
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 1.9 · 90% CI -26.7 to 31.0
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 23.6 · 90% CI -6.9 to 49.8
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 67.8 · 90% CI 36.4 to 85.3
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 41.7 · 90% CI 7.6 to 67.1
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 41.7 · 90% CI 7.6 to 67.1
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 55.0 · 90% CI 19.7 to 77.6
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 12.1 · 90% CI -21.4 to 43.4
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 3.8 · 90% CI -29.4 to 36.4
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 45.5 · 90% CI 17.1 to 69.0
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 36.4 · 90% CI 1.9 to 63.4
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 14.5 · 90% CI -21.4 to 47.0
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 24.5 · 90% CI -11.8 to 54.9
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -4.5 · 90% CI -40.4 to 32.3
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 13.6 · 90% CI -23.7 to 48.2
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 12.5 · 90% CI -28.0 to 49.3
SecondaryPercentage of Participants Achieving 75 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6 and 8

PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 75 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.

Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 75 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6 and 8
percentage of participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Week 1 (n= 14, 15, 16, 14)0.0 (0.0 to 19.3)0.0 (0.0 to 18.1)0.0 (0.0 to 17.1)7.1 (0.4 to 29.7)
Week 2 (n= 14, 14, 13, 12)7.1 (0.4 to 29.7)0.0 (0.0 to 19.3)15.4 (2.8 to 41.0)25.0 (7.2 to 52.7)
Week 3 (n= 13, 12, 15, 11)7.7 (0.4 to 31.6)0.0 (0.0 to 22.1)40.0 (19.1 to 64.0)36.4 (13.5 to 65.0)
Week 4 (n= 12, 12, 12, 10)16.7 (3.0 to 43.8)16.7 (3.0 to 43.8)50.0 (24.5 to 75.5)60.0 (30.4 to 85.0)
Week 5 (n= 11, 12, 12, 9)0.0 (0.0 to 23.8)25.0 (7.2 to 52.7)50.0 (24.5 to 75.5)66.7 (34.5 to 90.2)
Week 6 (n= 11, 11, 10, 10)18.2 (3.3 to 47.0)9.1 (0.5 to 36.4)60.0 (30.4 to 85.0)50.0 (22.2 to 77.8)
Week 8 (n= 8, 11, 11, 8)25.0 (4.6 to 60.0)9.1 (0.5 to 36.4)18.2 (3.3 to 47.0)25.0 (4.6 to 60.0)
Statistical analysis
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 7.1 · 90% CI -10.2 to 27.0
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -7.1 · 90% CI -27.0 to 10.2
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 8.2 · 90% CI -14.4 to 32.2
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 17.9 · 90% CI -6.7 to 43.6
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -7.7 · 90% CI -28.8 to 12.1
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 32.3 · 90% CI 5.4 to 55.4
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 28.7 · 90% CI 0.8 to 55.3
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 0.0 · 90% CI -27.3 to 27.3
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 33.3 · 90% CI 1.0 to 59.8
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 43.3 · 90% CI 8.8 to 69.3
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 25.0 · 90% CI 2.1 to 49.3
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 50.0 · 90% CI 25.4 to 71.8
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 66.7 · 90% CI 39.2 to 86.1
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -9.1 · 90% CI -36.3 to 18.3
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 41.8 · 90% CI 6.2 to 68.5
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 31.8 · 90% CI -2.9 to 60.5
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -15.9 · 90% CI -47.8 to 13.7
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: -6.8 · 90% CI -40.6 to 24.8
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 0.0 · 90% CI -36.4 to 36.4
SecondaryPercentage of Participants Achieving 90 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8

PASI score is combined assessment of lesion severity and area affected into single score range:0 (no disease) to 72 (maximal disease), with higher scores representing greater severity of psoriasis. Body divided into 4 sections (head and neck \[h\], arms \[u\], trunk \[t\], legs \[l\]); each area scored by itself and scores combined for final PASI score. For each section, percent body surface area (A) of skin involved was estimated:0 (no involvement) to 6 (90-100 percent involvement), severity estimated by clinical signs: erythema (E), induration (I), scaling (S); 5 point scale: 0 (no involvement) to 4 (very marked involvement). Final PASI score = 0.1Ah (Eh + Ih + Sh) + 0.2Au (Eu + Iu + Su) + 0.3At (Et + It + St) + 0.4Al (El + Il + Sl), where head: 0.1; upper limbs: 0.2; trunk: 0.3; lower limbs: 0.4). Participants who had at least 90 percent reduction in PASI score relative to baseline PASI Score are reported. 90 percent confidence intervals are calculated using clopper-pearson (exact) method.

Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90 Percent Reduction From Baseline PASI Score at Week 1, 2, 3, 4, 5, 6, and 8
percentage of participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Week 1 (n= 14, 15, 16, 14)0.0 (0.0 to 19.3)0.0 (0.0 to 18.1)0.0 (0.0 to 17.1)7.1 (0.4 to 29.7)
Week 2 (n= 14, 14, 13, 12)7.1 (0.4 to 29.7)0.0 (0.0 to 19.3)7.7 (0.4 to 31.6)8.3 (0.4 to 33.9)
Week 3 (n= 13, 12, 15, 11)0.0 (0.0 to 20.6)0.0 (0.0 to 22.1)13.3 (2.4 to 36.3)36.4 (13.5 to 65.0)
Week 4 (n= 12, 12, 12, 10)0.0 (0.0 to 22.1)0.0 (0.0 to 22.1)33.3 (12.3 to 60.9)60.0 (30.4 to 85.0)
Week 5 (n= 11, 12, 12, 9)0.0 (0.0 to 23.8)0.0 (0.0 to 22.1)25.0 (7.2 to 52.7)44.4 (16.9 to 74.9)
Week 6 (n= 11, 11, 10, 10)0.0 (0.0 to 23.8)0.0 (0.0 to 23.8)20.0 (3.7 to 50.7)30.0 (8.7 to 60.7)
Week 8 (n= 8, 11, 11, 8)0.0 (0.0 to 31.2)0.0 (0.0 to 23.8)0.0 (0.0 to 23.8)25.0 (4.6 to 60.0)
Statistical analysis
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 7.1 · 90% CI -10.2 to 27.0
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: -7.1 · 90% CI -27.0 to 10.2
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 0.5 · 90% CI -20.7 to 22.8
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 1.2 · 90% CI -20.3 to 24.8
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 13.3 · 90% CI -5.6 to 33.8
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 36.4 · 90% CI 15.3 to 61.1
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 33.3 · 90% CI 11.3 to 57.3
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 60.0 · 90% CI 34.7 to 80.9
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 25.0 · 90% CI 2.1 to 49.3
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 44.4 · 90% CI 19.4 to 70.2
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 20.0 · 90% CI -2.7 to 46.6
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 30.0 · 90% CI 6.4 to 56.4
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 25.0 · 90% CI -4.9 to 54.9
SecondaryPercentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear' at Week 1, 2, 3, 4, 5, 6, and 8

The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema (E), induration (I), and scaling (S) across all psoriatic lesions. The severity rating scores (erythema: 0= no evidence of erythema to 4= dark, deep red; Induration: 0= no evidence of plaque elevation to 4= marked plaque elevation, hard/sharp borders; Scaling: 0= no evidence of scaling to 4= thick, coarse scale predominates) were summed (E + I + S= total) and the average (total/3) was taken. The total average was rounded to the nearest whole number score to determine the PGA. The 5-point scale for PGA was: 0= clear; 1= almost clear; 2= mild; 3= moderate; 4= severe, where higher score indicating more severity. Participants with response of clear and almost clear were reported. 90 percent confidence intervals were calculated using clopper-pearson (exact) method.

Time frame:
Week 1, 2, 3, 4, 5, 6, 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Physician Global Assessment (PGA) Response of 'Clear' or 'Almost Clear' at Week 1, 2, 3, 4, 5, 6, and 8
percentage of participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Week 1 (n= 14, 15, 16, 14)0.0 (0.0 to 19.3)13.3 (2.4 to 36.3)12.5 (2.3 to 34.4)7.1 (0.4 to 29.7)
Week 2 (n= 14, 14, 13, 12)7.1 (0.4 to 29.7)28.6 (10.4 to 54.0)23.1 (6.6 to 49.5)41.7 (18.1 to 68.5)
Week 3 (n= 13, 12, 15, 11)15.4 (2.8 to 41.0)33.3 (12.3 to 60.9)46.7 (24.4 to 70.0)45.5 (20.0 to 72.9)
Week 4 (n= 12, 12, 12, 10)16.7 (3.0 to 43.8)41.7 (18.1 to 68.5)58.3 (31.5 to 81.9)70.0 (39.3 to 91.3)
Week 5 (n= 11, 12, 12, 9)27.3 (7.9 to 56.4)33.3 (12.3 to 60.9)41.7 (18.1 to 68.5)77.8 (45.0 to 95.9)
Week 6 (n= 11, 11, 10, 10)36.4 (13.5 to 65.0)45.5 (20.0 to 72.9)40.0 (15.0 to 69.6)50.0 (22.2 to 77.8)
Week 8 (n= 8, 11, 11, 8)25.0 (4.6 to 60.0)27.3 (7.9 to 56.4)45.5 (20.0 to 72.9)37.5 (11.1 to 71.1)
Statistical analysis
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 13.3 · 90% CI -4.4 to 33.8
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 12.5 · 90% CI -5.2 to 32.0
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 7.1 · 90% CI -10.2 to 27.0
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 21.4 · 90% CI -3.2 to 45.5
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 15.9 · 90% CI -8.1 to 40.7
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 34.5 · 90% CI 7.3 to 59.4
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 17.9 · 90% CI -11.2 to 45.5
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 31.3 · 90% CI 1.7 to 55.7
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in Percentage Analysed using · Difference in percentage: 30.1 · 90% CI -1.2 to 57.4
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 25.0 · 90% CI -6.4 to 52.5
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 41.7 · 90% CI 8.7 to 66.7
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 53.3 · 90% CI 18.5 to 76.6
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 6.1 · 90% CI -26.1 to 36.6
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 14.4 · 90% CI -18.9 to 44.5
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 50.5 · 90% CI 12.9 to 75.3
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 9.1 · 90% CI -25.2 to 41.4
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 3.6 · 90% CI -30.5 to 37.3
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 13.6 · 90% CI -21.9 to 46.2
  • Placebo vs PF-04965842 200 Milligram (mg) Once Daily · Difference in percentage: 2.3 · 90% CI -33.2 to 34.6
  • Placebo vs PF-04965842 400 mg Once Daily · Difference in percentage: 20.5 · 90% CI -17.6 to 51.9
  • Placebo vs PF-04965842 200 mg Twice Daily · Difference in percentage: 12.5 · 90% CI -26.4 to 48.1
SecondaryChange From Baseline in Fasting Lipids at Week 2, 4 and 8

Participants were required to fast 9 hours prior to sampling for lipid profile which included following parameters: low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), cholesterol, triglycerides.

Time frame:
Baseline, Week 2, 4, 8 (early termination)
Reported as:
Mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Lipids at Week 2, 4 and 8
milligram per deciliter (mg/dL)PlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Baseline: (n= 14, 15. 16, 14)119.07 ± 24.780105.27 ± 28.632114.56 ± 28.317113.93 ± 31.770
LDL-C: Change at Week 2 (n= 13, 14, 14, 12)-6.31 ± 16.82518.50 ± 31.0353.21 ± 25.09726.92 ± 24.748
LDL-C: Change at Week 4 (n= 12, 12, 12, 10)-2.50 ± 11.35026.75 ± 26.45510.17 ± 22.14315.20 ± 30.904
LDL-C: Change at Week 8 (n= 7, 11, 10, 8)7.14 ± 20.6596.00 ± 16.529-3.20 ± 12.072-15.13 ± 20.301
HDL-C: Baseline (n= 14, 15, 16, 14)52.93 ± 12.64046.47 ± 11.23049.06 ± 15.05850.29 ± 10.163
HDL-C: Change at Week 2 (n= 13, 14, 14, 12)-1.54 ± 7.88110.00 ± 5.53310.64 ± 9.29514.00 ± 8.113
HDL-C: Change at Week 4 (n= 12, 12, 12, 10)-1.00 ± 6.2389.25 ± 6.71712.25 ± 10.43712.80 ± 10.075
HDL-C: Change at Week 8 (n= 7, 11, 10, 8)-2.43 ± 10.737-2.36 ± 2.730-0.40 ± 6.275-5.00 ± 6.234
Cholesterol: Baseline (n= 14, 15, 16, 14)195.43 ± 30.137186.80 ± 25.741188.75 ± 32.298191.14 ± 36.469
Cholesterol: Change at Week 2 (n= 13, 14, 14 12)-0.77 ± 14.80029.57 ± 31.32921.00 ± 34.00544.08 ± 23.469
Cholesterol: Change at Week 4 (n= 12, 12, 12, 10)-3.50 ± 20.17440.08 ± 25.06227.25 ± 22.91926.40 ± 29.220
Cholesterol: Change at Week 8 (n= 7, 11, 10, 8)9.86 ± 24.3617.45 ± 14.733-1.20 ± 20.395-10.88 ± 23.991
Triglycerides: Baseline (n= 14, 15, 16, 14)116.64 ± 47.490175.00 ± 74.971125.50 ± 50.552134.21 ± 53.903
Triglycerides: Change at Week 2 (n= 13, 14, 14 12)35.85 ± 49.17323.79 ± 72.63835.86 ± 47.33715.83 ± 43.151
Triglycerides: Change at Week 4 (n=12, 12, 12, 10)0.67 ± 42.47035.67 ± 80.71424.00 ± 66.766-7.30 ± 44.144
Triglycerides: Change at Week 8 (n= 7, 11, 10, 8)48.71 ± 102.30141.09 ± 68.40512.20 ± 44.43446.50 ± 62.198
SecondaryChange From Baseline in Lipid Ratios at Week 2, 4 and 8

The ratio of LDL-C/HDL-C was reported.

Time frame:
Baseline, Week 2, 4, 8 (early termination)
Reported as:
Mean · ratio
Change From Baseline in Lipid Ratios at Week 2, 4 and 8
ratioPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
LDL-C: HDL C; Baseline (n= 14,15,16,14)2.35 ± 0.7452.39 ± 0.9152.48 ± 0.7352.37 ± 0.912
LDL-C: HDL C; Change at Week 2 (n=13,14,14,12)0.02 ± 0.449-0.05 ± 0.593-0.33 ± 0.384-0.03 ± 0.367
LDL C: HDL C; Change at Week 4 (n= 12, 12, 12, 10)0.01 ± 0.2180.11 ± 0.552-0.30 ± 0.468-0.07 ± 0.813
LDL C: HDL C; Change at Week 8 (n=7,11,10, 8)0.37 ± 0.3810.32 ± 0.439-0.07 ± 0.324-0.04 ± 0.362
SecondaryChange From Baseline in High Sensitivity C- Reactive Protein (hsCRP) at Week 1, 2, 3, 4, and 8

The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Reference range for measurements is 0-0.5 mg/dL and lower limit of detection is less than (\<) 0.015 mg/dL. Any value \<0.015 mg/dL is imputed as 0.0075 mg/dL.

Time frame:
Baseline, Week 1, 2, 3, 4, 8 (early termination)
Reported as:
Mean · mg/dL
Change From Baseline in High Sensitivity C- Reactive Protein (hsCRP) at Week 1, 2, 3, 4, and 8
mg/dLPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Baseline (n= 14, 15, 16, 14)0.6056 ± 1.052800.6718 ± 0.715270.3325 ± 0.288540.4994 ± 0.43345
Change at Week 1 (n= 14, 15, 16, 14)-0.1451 ± 0.37322-0.5495 ± 0.66033-0.2288 ± 0.26512-0.3807 ± 0.49723
Change at Week 2 (n= 13, 14, 14, 12)-0.1712 ± 0.49223-0.4540 ± 0.80459-0.1783 ± 0.27518-0.3374 ± 0.49736
Change at Week 3 (n= 12, 12, 15, 11)0.0323 ± 0.617461.2447 ± 5.21627-0.0471 ± 0.45332-0.2214 ± 0.48102
Change at Week 4 (n= 11, 12, 12, 10)-0.0284 ± 0.64387-0.4093 ± 0.831690.1162 ± 0.95838-0.0850 ± 0.63410
Change at Week 8 (n= 7, 11, 11, 8)-0.5996 ± 1.17921-0.2473 ± 0.942490.2521 ± 0.53698-0.0081 ± 0.16782
SecondaryNumber of Participants Reporting Clinically Significant Change From Baseline in Epstein-Barr Virus (EBV) Values

EBV samples were collected and changes from baseline were evaluated by the principal investigator (PI) for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in adverse event (AEs) or required follow-up.

Time frame:
Baseline up to Week 8 (early termination)
Reported as:
Number · participants
Number of Participants Reporting Clinically Significant Change From Baseline in Epstein-Barr Virus (EBV) Values
participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Number of Participants Reporting Clinically Significant Change From Baseline in Epstein-Barr Virus (EBV) Values0000
SecondaryNumber of Participants Reporting Clinically Significant Change From Baseline in Cytomegalovirus (CMV) Values

CMV samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.

Time frame:
Baseline up to Week 8 (early termination)
Reported as:
Number · participants
Number of Participants Reporting Clinically Significant Change From Baseline in Cytomegalovirus (CMV) Values
participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Number of Participants Reporting Clinically Significant Change From Baseline in Cytomegalovirus (CMV) Values0000
SecondaryNumber of Participants Reporting Clinically Significant Change From Baseline in Herpes Simplex Virus Deoxyribonucleic Acid (HSV DNA) Values

HSV DNA samples were collected and changes from baseline were evaluated by the PI for clinical significance. Clinical significance is levels outside of the normal range (abnormal levels) with clinically apparent viral disease, or that resulted in AEs or required follow-up.

Time frame:
Baseline up to Week 8 (early termination)
Reported as:
Number · participants
Number of Participants Reporting Clinically Significant Change From Baseline in Herpes Simplex Virus Deoxyribonucleic Acid (HSV DNA) Values
participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Number of Participants Reporting Clinically Significant Change From Baseline in Herpes Simplex Virus Deoxyribonucleic Acid (HSV DNA) Values0000
SecondaryChange From Baseline in Blood Pressure (BP) at Week 1, 2, 3, 4, 5, 6, and 8
Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Reported as:
Mean · millimeter of mercury (mmHg)
Change From Baseline in Blood Pressure (BP) at Week 1, 2, 3, 4, 5, 6, and 8
millimeter of mercury (mmHg)PlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Systolic BP: Baseline (n= 14,15,16,14)125.4 ± 11.77125.5 ± 11.46124.7 ± 12.97128.0 ± 11.50
Systolic BP: Change at Week 1 (n= 14, 15, 16, 14)-2.1 ± 9.64-1.5 ± 10.940.6 ± 8.872.0 ± 10.88
Systolic BP: Change at Week 2 (n= 13, 13, 14, 10)-0.3 ± 6.73-1.6 ± 9.463.9 ± 8.01-0.4 ± 7.68
Systolic BP: Change at Week 3 (n= 12, 12, 14, 10)-4.5 ± 7.09-3.3 ± 7.826.7 ± 16.82-1.0 ± 13.65
Systolic BP: Change at Week 4 (n= 12, 12, 12, 10)-2.3 ± 5.66-5.8 ± 12.400.2 ± 7.441.7 ± 15.44
Systolic BP: Change at Week 5 (n= 11, 12, 12, 9)-2.9 ± 9.98-0.8 ± 8.29-0.3 ± 10.372.0 ± 18.08
Systolic BP: Change at Week 6 (n= 11, 12, 12, 10)-5.7 ± 8.95-1.3 ± 7.99-2.0 ± 8.86-0.2 ± 11.37
Systolic BP: Change at Week 8 (n= 14, 14, 13, 13)-2.3 ± 12.96-2.1 ± 9.61-2.1 ± 7.123.5 ± 11.49
Diastolic BP: Baseline (n=14,15,16,14)77.1 ± 7.3976.5 ± 6.8477.4 ± 9.8579.9 ± 10.73
Diastolic BP: Change at Week 1 (n=14,15,16,14)0.0 ± 6.880.9 ± 6.970.8 ± 9.992.0 ± 10.02
Diastolic BP: Change at Week 2 (n=13,13,14,10)0.6 ± 8.081.5 ± 8.96-0.4 ± 9.132.5 ± 6.08
Diastolic BP: Change at Week 3 (n=12,12,14,10)-0.7 ± 8.17-0.9 ± 7.501.1 ± 7.760.3 ± 10.70
Diastolic BP Change at Week 4 (n=12,12,12,10)-2.5 ± 8.21-2.3 ± 6.611.2 ± 5.462.4 ± 9.58
Diastolic BP: Change at Week 5 (n= 11, 12, 12, 9)0.8 ± 5.130.0 ± 5.640.4 ± 5.621.8 ± 10.32
Diastolic BP: Change at Week 6 (n=11,12,12,10)0.5 ± 5.912.1 ± 6.36-2.8 ± 5.670.9 ± 7.49
Diastolic BP: Change at Week 8 (n= 14,14,13,13)-1.1 ± 8.12-0.6 ± 6.081.5 ± 9.771.4 ± 9.26
SecondaryChange From Baseline in Pulse Rate at Week 1, 2, 3, 4, 5, 6, and 8
Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in Pulse Rate at Week 1, 2, 3, 4, 5, 6, and 8
beats per minute (bpm)PlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Baseline (n= 14, 15, 16, 14)67.6 ± 7.8771.8 ± 11.8572.2 ± 11.5472.6 ± 9.64
Change at Week 1 (n= 14, 15, 16, 14)1.0 ± 6.50-0.2 ± 8.510.0 ± 10.56-4.3 ± 7.43
Change at Week 2 (n= 13, 13, 14, 10)2.8 ± 9.97-4.7 ± 9.39-2.4 ± 8.50-2.8 ± 8.48
Change at Week 3 (n= 12, 12, 14, 10)4.1 ± 15.09-1.3 ± 10.76-1.5 ± 11.06-2.3 ± 6.88
Change at Week 4 (n= 12, 12, 12, 10)-1.3 ± 9.69-1.3 ± 12.89-4.7 ± 10.870.5 ± 9.37
Change at Week 5 (n= 11, 12, 12, 9)5.2 ± 12.752.7 ± 10.44-0.8 ± 10.347.8 ± 11.11
Change at Week 6 (n= 11, 12, 12, 10)4.5 ± 12.36-1.8 ± 11.462.4 ± 8.534.7 ± 9.15
Change at Week 8 (n= 14, 14, 13, 13)0.9 ± 11.96-0.6 ± 13.87-5.3 ± 11.29-1.2 ± 8.12
SecondaryChange From Baseline in Respiratory Rate at Week 1, 2, 3, 4, 5, 6, and 8
Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Reported as:
Mean · respiration per minute (resp/min)
Change From Baseline in Respiratory Rate at Week 1, 2, 3, 4, 5, 6, and 8
respiration per minute (resp/min)PlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Baseline (n= 14, 15, 16, 13)16.2 ± 1.5817.1 ± 3.6716.3 ± 2.4417.0 ± 2.16
Change at Week 1 (n= 14, 15, 16, 13)-0.5 ± 1.700.9 ± 1.98-0.1 ± 0.81-0.3 ± 1.60
Change at Week 2 (n= 13, 13, 14, 9)-0.5 ± 1.450.4 ± 1.71-0.6 ± 1.820.7 ± 2.65
Change at Week 3 (n= 12, 12, 14, 9)-0.3 ± 0.87-0.6 ± 1.51-0.4 ± 1.690.2 ± 1.56
Change at Week 4 (n= 12, 12, 12, 9)0.2 ± 2.12-0.7 ± 1.72-1.2 ± 1.750.0 ± 1.41
Change at Week 5 (n= 11, 12, 12, 8)0.1 ± 1.450.3 ± 2.30-0.9 ± 1.78-0.6 ± 1.92
Change at Week 6 (n= 11, 12, 12, 9)-0.4 ± 0.810.2 ± 1.34-0.8 ± 1.54-0.2 ± 1.20
Change at Week 8 (n= 14, 14, 13, 12)-0.3 ± 1.49-0.2 ± 2.01-0.8 ± 1.30-1.0 ± 1.60
SecondaryChange From Baseline in Body Temperature at Week 1, 2, 3, 4, 5, 6, and 8
Time frame:
Baseline, Week 1, 2, 3, 4, 5, 6, 8 (early termination)
Reported as:
Mean · degree celsius
Change From Baseline in Body Temperature at Week 1, 2, 3, 4, 5, 6, and 8
degree celsiusPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Baseline (n= 14, 15, 16, 14)36.49 ± 0.36336.59 ± 0.27436.67 ± 0.28236.57 ± 0.433
Change at Week 1 (n= 14, 15, 16, 14)-0.01 ± 0.264-0.03 ± 0.3220.00 ± 0.265-0.17 ± 0.271
Change at Week 2 (n= 13, 13, 14, 10)-0.04 ± 0.366-0.22 ± 0.397-0.05 ± 0.509-0.05 ± 0.273
Change at Week 3 (n= 12, 12, 14, 10)-0.04 ± 0.391-0.21 ± 0.510-0.11 ± 0.2870.09 ± 0.501
Change at Week 4 (n= 12, 12, 12, 10)-0.07 ± 0.467-0.21 ± 0.362-0.02 ± 0.346-0.12 ± 0.477
Change at Week 5 (n= 11, 12, 12, 9)0.21 ± 0.3160.07 ± 0.3180.01 ± 0.3050.13 ± 0.443
Change at Week 6 (n= 10, 12, 12, 10)0.05 ± 0.328-0.00 ± 0.292-0.07 ± 0.2690.00 ± 0.390
Change at Week 8 (n= 14, 14, 13, 13)0.10 ± 0.332-0.01 ± 0.361-0.05 ± 0.3260.07 ± 0.426
SecondaryNumber of Participants Reporting Clinically Significant Change From Baseline in Heart Rate
Time frame:
Baseline up to Week 8 (early termination)
Reported as:
Number · bpm
Number of Participants Reporting Clinically Significant Change From Baseline in Heart Rate
bpmPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Number of Participants Reporting Clinically Significant Change From Baseline in Heart Rate0000
SecondaryNumber of Participants Reporting Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters

ECG change data was reported as qualitative results, as per change in planned analysis. It was categorized as: normal; abnormal, not clinically significant or abnormal, clinically significant.

Time frame:
Baseline up to Week 8 (early termination)
Reported as:
Number · participants
Number of Participants Reporting Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters
participantsPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Number of Participants Reporting Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters0000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/14 (7.1%)6/14 (42.9%)
PF-04965842 200 Milligram (mg) Once Daily—0/15 (0%)7/15 (46.7%)
PF-04965842 400 mg Once Daily—0/16 (0%)14/16 (87.5%)
PF-04965842 200 mg Twice Daily—0/14 (0%)11/14 (78.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
Transient ischaemic attackNervous system disorders1/140/150/160/14
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice Daily
ThrombocytopeniaBlood and lymphatic system disorders0/140/150/165/14
HeadacheNervous system disorders2/141/155/161/14
NauseaGastrointestinal disorders1/142/154/163/14
NeutropeniaBlood and lymphatic system disorders1/140/151/163/14
Platelet count decreasedInvestigations0/140/151/163/14
ContusionInjury, poisoning and procedural complications1/140/150/162/14
White blood cell count decreasedInvestigations0/141/150/162/14
HypertensionVascular disorders0/140/152/161/14
LeukopeniaBlood and lymphatic system disorders0/140/150/161/14
White blood cell disorderBlood and lymphatic system disorders1/140/150/160/14

Baseline characteristics

The full analysis set (FAS) included all randomized participants who received at least 1 dose of the randomized study drug (PF-04965842 or placebo).

Age, Continuous
Age, Continuous(years)PlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice DailyTotal
Mean45.4 ± 10.842.9 ± 12.342.8 ± 11.652.1 ± 9.745.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-04965842 200 Milligram (mg) Once DailyPF-04965842 400 mg Once DailyPF-04965842 200 mg Twice DailyTotal
Female355619
Male111011840
08

Study locations

45 sites
  • Total Skin and Beauty Dermatology Center, PC
    Birmingham, Alabama 32505, United States
  • Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA
    Rogers, Arkansas 72758, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Dermatology Specialists, Inc.
    Oceanside, California 92056, United States
  • Huntington Medical Foundation/Specialty Office
    Pasadena, California 91105, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Olympian Clinical Research
    Clearwater, Florida 33756, United States
  • Westcoast Radiology Services
    Clearwater, Florida 33756, United States
  • North Florida Dermatology Associates, PA
    Jacksonville, Florida 32204, United States
  • International Dermatology Research, Inc.
    Miami, Florida 33144, United States
  • Park Avenue Dermatology, PA
    Orange Park, Florida 32073, United States
  • Leavitt Medical Associates of Florida d/b/a Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Advanced Medical Research, Inc
    Atlanta, Georgia 30342, United States
  • Columbus Dermatology, P.C.
    Columbus, Georgia 31904, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46256, United States
  • Dawes Fretzin Dermatology Group, LLC
    Indianapolis, Indiana 46256, United States
  • DS Research
    Louisville, Kentucky 40202, United States
  • Shondra L Smith, MD
    Lake Charles, Louisiana 70605, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Dartmouth-Hitchcock Medical Center - Section of Dermatology
    Lebanon, New Hampshire 03756, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Duke University Medical Center - Shipment Only
    Durham, North Carolina 27710, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Partners, LLC
    Johnston, Rhode Island 02919, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Arlington Research Center, Inc.
    Arlington, Texas 76011, United States
  • Dermatology Treatment & Research Center, PA
    Dallas, Texas 75230, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23507, United States
  • Premier Clinical Research
    Spokane, Washington 99202-1480, United States
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Co-Medica Research Network Inc.
    Courtice, Ontario L1E 3C3, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • Research by ICLS
    Oakville, Ontario L6J 7W5, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology & Cosmetic
    Richmond Hill, Ontario L4B 1A5, Canada
  • K.Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • Dr Isabelle Delorme Inc.
    Drummondville, Quebec J2B 5L4, Canada
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • Q & T Research Sherbrooke Inc.
    Sherbrooke, Quebec J1J 2G2, Canada
09

References and documents

Publications

  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib. Br J Clin Pharmacol. 2022 Aug;88(8):3856-3871. doi: 10.1111/bcp.15334. Epub 2022 Apr 11. PubMed 35342978 ↗
  • Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 May;61(5):709-723. doi: 10.1007/s40262-021-01104-z. Epub 2022 Jan 21. Erratum In: Clin Pharmacokinet. 2022 Apr;61(4):591. doi: 10.1007/s40262-022-01112-7. PubMed 35061234 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2014
First posted
Jul 28, 2014
Start
Nov 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Oct 5, 2016
Last update
Oct 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02201524
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 28, 2014
Start date
Nov 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Oct 5, 2016
Last update
Oct 5, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion